Tilahun Anemut, Chekol Endeshaw, Teklemaryam Awgchew Behaile, Agidew Melaku Mekonnen, Tilahun Zelalem, Admassu Fitalew Tadele, Dagnaw Nega, Mengstie Misganaw Asmamaw, Amsalu Alebachew, Mengistu Enyew Fenta, Akelew Yibeltal, Asmamaw Tadesse, Bantie Berihun
Department of Biomedical Sciences, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Department of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Heliyon. 2022 Oct 29;8(11):e11342. doi: 10.1016/j.heliyon.2022.e11342. eCollection 2022 Nov.
Highly active anti-retroviral therapy has been reported to be associated with a number of side effects in human immunodeficiency virus patients among which dyslipidemia isa common metabolic disorder.
A Hospital based comparative cross-sectional study among 228 HIV positive patients was conducted from July to August 2020. Socio-demographic and clinical data were collected using structured questionnaires. Fasting venous blood sample was collected and analyzed for Lipid profiles. EDTA sample was analyzed for CD4+ T cell determination Anthropometric measurement was done. Data were analyzed using SPSS version 22. Independent t-test was done. Logistic and binary regression was done.
A total of 228 HIV patients were enrolled in the study. Prevalence of dyslipidemia in HAART naive and HAART treated patients was 61 (53.5%) and 84 (73.7%), respectively. The prevalence of Total Cholesterol ≥200 mg/dl was 50% and 30%; High density lipoprotein cholesterol <40 mg/dl was 43.8% and 36%; Low density lipoprotein cholesterol ≥130 mg/dl was 48.3% and 28.1%; and Triglyceride ≥ 150 mg/dl 59.6% and 39% among HAART treated and HAART naive, respectively. Age greater than 40 years (AOR = 3.27, 95% C.I: 1.47-7.25), blood pressure ≥140/90 (AOR = 16.13, 95% C.I: 5.81-44.75), being on HAART (AOR = 2.73, 95% C.I: 1.35-5.53) and body mass index >25 kg/m (AOR = 1.92, 95% C.I: 1.20-4.81) were identified as determinants of dyslipidemia.
The mean value of lipid profile was significantly higher among HAART treated as compared to those HAART naive HIV positive clients.
据报道，高效抗逆转录病毒疗法与人类免疫缺陷病毒患者的多种副作用有关，其中血脂异常是一种常见的代谢紊乱。
2020年7月至8月，在228例HIV阳性患者中开展了一项基于医院的比较性横断面研究。使用结构化问卷收集社会人口学和临床数据。采集空腹静脉血样本并分析血脂谱。采集乙二胺四乙酸（EDTA）样本用于测定CD4+T细胞。进行人体测量。使用SPSS 22版软件对数据进行分析。进行独立t检验、逻辑回归和二元回归分析。
本研究共纳入228例HIV患者。初治和接受高效抗逆转录病毒治疗（HAART）的患者中血脂异常的患病率分别为61例（53.5%）和84例（73.7%）。总胆固醇≥200mg/dl的患病率分别为50%和30%；高密度脂蛋白胆固醇<40mg/dl的患病率分别为43.8%和36%；低密度脂蛋白胆固醇≥130mg/dl的患病率分别为48.3%和28.1%；甘油三酯≥150mg/dl的患病率在接受HAART治疗的患者和初治患者中分别为59.6%和39%。年龄大于40岁（比值比[AOR]=3.27，95%置信区间[C.I]：1.47 - 7.25）、血压≥140/90（AOR = 16.13，95% C.I：5.81 - 44.75）、接受HAART治疗（AOR = 2.73，95% C.I：1.35 - 5.53）和体重指数>25kg/m²（AOR = 1.92，95% C.I：1.20 - 4.81）被确定为血脂异常的决定因素。
与初治的HIV阳性患者相比，接受HAART治疗的患者血脂谱平均值显著更高。
